Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS) (BiC-8)
Acute Myocardial Infarction
About this trial
This is an interventional diagnostic trial for Acute Myocardial Infarction focused on measuring Copeptin, Troponin, Acute Coronary Syndrome, Rule-out of acute myocardial infarction, Emergency Medicine
Eligibility Criteria
Inclusion Criteria:
- Typical chest pain (with or without ECG-changes, but no ST-elevation)suggestive of unstable angina or non-ST-elevated myocardial infarction (NSTEMI)
- Troponin negative at admission according to the current clinical practice Patient willing and able to give written informed consent
Exclusion Criteria:
- Patients with ST-elevation myocardial infarction (STEMI)
- Continuing chest pain or recurrent episodes of chest pain under therapy
- High-risk patients with suspected ACS who need to be hospitalized for reasons independent of their initial troponin result
- Patients who need to be hospitalized for other medical reasons
- Patients in need of urgent life-saving interventions
- Patients under 18 years of age
- Patients with a life expectancy < 6 months
- Patients with any condition that leads the treating physician to not consider the patient eligible for the trial
Sites / Locations
- Wilhelminenspital Vienna
- Kerckhoff-Klinik GmbH
- Charité - Universitätsmedizin Berlin
- Universitätsklinikum Hamburg-Eppendorf
- Universitätsklinikum Heidelberg
- University Hospital Basel
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Copeptin
Standard
Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software "Praxis-connect" i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room. Patients who test positive for Copeptin will be treated as by standard practise.
Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.